Immunovant Announces Topline Results From Proof-Of-Concept Study Of Imvt-1402 In Cutaneous Lupus Erythematosus
IMVT•Topline study results in cutaneous lupus erythematosus
Sept. 23 (Reuters) - Immunovant, Inc. (Nasdaq: IMVT):
- Immunovant announces topline results from proof-of-concept study of IMVT-1402 in cutaneous lupus erythematosus.
- The IMVT-1402 study in CLE did not achieve statistical significance on the primary endpoint.
- Immunovant said it will stop development of IMVT-1402 in CLE.
- IMVT-1402 demonstrated a favorable safety and tolerability profile.
- All other clinical development timelines remain on track.
Source text: ID:nGNXbDxZ5G
Further company coverage: IMVT.O
